Table 1.
Patient Demographics of Training Cohort
| Characteristics | Total Patients | No Late Recurrence | Late Recurrence | p-value |
|---|---|---|---|---|
| n | 339 | 252 (74.34%) | 87 (25.66%) | |
| aMAP Score | <0.001 | |||
| ≤64.2 | 228 | 200 (79.37%) | 28 (32.18%) | |
| 64.3–68.6 | 73 | 47 (18.65%) | 26 (29.89%) | |
| ≥68.7 | 38 | 5 (1.98%) | 33 (37.93%) | |
| Age (years) | 0.169 | |||
| ≤60 | 217 | 156 (61.90%) | 61 (70.11%) | |
| >60 | 122 | 96 (38.10%) | 26 (29.89%) | |
| Gender | <0.001 | |||
| Female | 54 | 52 (20.63%) | 2 (2.30%) | |
| Male | 285 | 200 (79.37%) | 85 (97.70%) | |
| Max Size (cm) | 0.019 | |||
| ≤3.0 | 266 | 190 (75.40%) | 76 (87.36%) | |
| >3.0 | 73 | 62 (24.60%) | 11 (12.64%) | |
| Number | <0.001 | |||
| Solitary | 247 | 213 (84.52%) | 34 (39.08%) | |
| Multiple | 92 | 39 (15.48%) | 53 (60.92%) | |
| Ablation sessions | 0.855 | |||
| 1 | 298 | 222 (88.10%) | 76 (87.36%) | |
| 2 | 41 | 30 (11.90%) | 11 (12.64%) | |
| Location | 0.148 | |||
| Favorable | 309 | 233 (92.46%) | 76 (87.36%) | |
| Unfavorable | 30 | 19 (7.54%) | 11 (12.64%) | |
| Etiology | 0.909 | |||
| HBV | 302 | 225 (89.28%) | 77 (88.50%) | |
| HCV | 31 | 23 (9.13%) | 8 (9.20%) | |
| Alcoholic | 6 | 4 (1.59%) | 2 (2.30%) | |
| Antiviral Therapy | 0.013 | |||
| No | 141 | 95 (37.70%) | 46 (52.87%) | |
| Yes | 198 | 157 (62.30%) | 41 (47.13%) | |
| Cirrhosis | 0.002 | |||
| No | 38 | 36 (14.29%) | 2 (2.30%) | |
| Yes | 301 | 216 (85.71%) | 85 (97.70%) | |
| Child-Pugh class | 0.311 | |||
| A | 178 | 131 (51.98%) | 47 (54.02%) | |
| B | 161 | 121 (48.02%) | 40 (45.98%) | |
| ALBI grade | 0.743 | |||
| 1 | 178 | 131 (51.98%) | 47 (54.02%) | |
| 2 | 161 | 121 (48.02%) | 40 (45.98%) | |
| AFP (ng/mL) | 0.347 | |||
| ≤400 | 307 | 226 (89.68%) | 81 (93.10%) | |
| >400 | 32 | 26 (10.32%) | 6 (6.90%) | |
| ALB (g/L) | 0.073 | |||
| ≤35 | 37 | 32 (12.70%) | 5 (5.75%) | |
| >35 | 302 | 220 (87.30%) | 82 (94.25%) | |
| AST (U/L) | 0.897 | |||
| ≤40 | 279 | 207 (82.14%) | 72 (82.76%) | |
| >40 | 60 | 45 (17.86%) | 15 (17.24%) | |
| ALT (U/L) | 0.656 | |||
| ≤40 | 76 | 55 (21.83%) | 21 (24.14%) | |
| >40 | 263 | 197 (78.17%) | 66 (75.86%) | |
| PLT (109/L) | 0.241 | |||
| ≤100 | 134 | 95 (37.70%) | 39 (44.83%) | |
| >100 | 205 | 157 (62.30%) | 48 (55.17%) | |
| TBIL (μmol/L) | 0.452 | |||
| ≤17.1 | 214 | 162 (64.29%) | 52 (59.77%) | |
| >17.1 | 125 | 90 (35.71%) | 35 (40.23%) | |
| γ-GT (U/L) | 0.769 | |||
| ≤60 | 238 | 178 (70.63%) | 60 (68.97%) | |
| >60 | 101 | 74 (29.37%) | 27 (31.03%) |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; ALB, albumin; AST, aspartic transaminase; ALT, alanine aminotransferase; TBIL, total bilirubin; PLT, platelet; γ-GT, γ-glutamyl transpeptidase.